摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-甲基咪唑-4-甲酸乙酯 | 41507-56-6

中文名称
1-甲基咪唑-4-甲酸乙酯
中文别名
1-甲基咪唑-4-羧酸乙酯
英文名称
ethyl 1-methyl-1H-imidazole-4-carboxylate
英文别名
ethyl 1-methylimidazole-4-carboxylate
1-甲基咪唑-4-甲酸乙酯化学式
CAS
41507-56-6
化学式
C7H10N2O2
mdl
——
分子量
154.169
InChiKey
CYPCWFKNFJRMQN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    294.9±13.0 °C(Predicted)
  • 密度:
    1.14±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933290090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:23824a86ff75edf21097416e91792edd
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Ethyl 1-methylimidazole-4-carboxylate
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 1-methylimidazole-4-carboxylate
CAS number: 41507-56-6

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2
Molecular weight: 154.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

反应信息

  • 作为反应物:
    描述:
    1-甲基咪唑-4-甲酸乙酯sodium hydroxide 作用下, 以 为溶剂, 反应 0.17h, 生成 N1-methyl-4-carboxyimidazole, sodium salt
    参考文献:
    名称:
    Alenin, V. V.; Kostikova, T. R.; Domkin, V. D., Journal of general chemistry of the USSR, 1987, vol. 57, p. 609 - 617
    摘要:
    DOI:
  • 作为产物:
    描述:
    2-氨基-2-氰基乙酸乙酯盐酸磷酸sodium ethanolate 、 sodium nitrite 作用下, 以 为溶剂, 反应 7.0h, 生成 1-甲基咪唑-4-甲酸乙酯
    参考文献:
    名称:
    Alenin, V. V.; Kostikova, T. R.; Domkin, V. D., Journal of general chemistry of the USSR, 1987, vol. 57, p. 609 - 617
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • C–H arylation and alkenylation of imidazoles by nickel catalysis: solvent-accelerated imidazole C–H activation
    作者:Kei Muto、Taito Hatakeyama、Junichiro Yamaguchi、Kenichiro Itami
    DOI:10.1039/c5sc02942b
    日期:——

    The first nickel-catalyzed C–H arylations and alkenylations of imidazoles with phenol and enol derivatives are described.

    第一个镍催化的咪唑与酚和烯醇衍生物的C-H芳基化和烯基化反应被描述了。
  • [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078454A1
    公开(公告)日:2014-05-22
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    公式I的化合物:或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C和X如本文定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
  • [EN] IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS IMIDAZOPYRROLIDINONE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
    申请人:NOVARTIS AG
    公开号:WO2014191894A1
    公开(公告)日:2014-12-04
    The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    本发明提供了化合物(I)或其药学上可接受的盐;制造本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和药物组合物。
  • Synthesis and Structure-Activity Relationships of New (5R,8R,10R)-Ergoline Derivatives with Antihypertensive or Dopaminergic Activity.
    作者:Sachio OHNO、Yuko ADACHI、Masayuki KOUMORI、Kiyoshi MIZUKOSHI、Mitsuaki NAGASAKA、Kenji ICHIHARA、Ei-ichi KATO
    DOI:10.1248/cpb.42.1463
    日期:——
    containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18-fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active
    合成了一系列新的(5R,8R,10R)-麦角灵衍生物,并在有意识的自发性高血压大鼠和单侧6-羟基多巴胺诱导的黑质病变大鼠中测试了它们的降压和多巴胺能活性。由相应的麦角灵羧酸酯制备的(5R,8R,10R)-6-烷基-8-麦角灵甲醇被转化为甲苯磺酸酯,然后用各种含氮原子的五元杂环进行处理,得到新的麦角灵。(5R,8R,10R)-8-(1,2,4-三唑-1-基甲基)-6-甲基麦角灵(4s,马来酸酯:BAM-1110)表现出强力的多巴胺能活性,比溴隐亭高约18倍甲磺酸酯 (5R,8R,10R)-8-(1,2,4-三唑-1-基甲基)-6-丙基麦角灵(8b,富马酸酯:BAM-1602)显示出极强的多巴胺能活性,约为220和1。活性分别比溴隐亭甲磺酸盐和甲磺酸培高利特高15倍。几种化合物表现出有效的抗高血压活性。讨论了抗高血压和多巴胺能活动的构效关系。
  • [EN] FUNGICIDAL OXADIAZOLES<br/>[FR] OXADIAZOLES À ACTIVITÉ FONGICIDE
    申请人:FMC CORP
    公开号:WO2018118781A1
    公开(公告)日:2018-06-28
    Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, A, and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.
    公开的是Formula 1的化合物,包括所有的几何和立体异构体、互变异构体、N-氧化物及其盐,其中R1、A和J如披露中所定义。还公开了含有Formula 1化合物的组合物,以及控制由真菌病原体引起的植物疾病的方法,包括施用本发明的化合物或组合物的有效量。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺